Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome

Next Previous
Trial Profile

A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telitacicept (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Sponsors RemeGen

Most Recent Events

  • 25 Jul 2023 Results published in the RemeGen Media Release.
  • 03 Jul 2023 Primary endpoint (The amount of change of European League Against Rheumatism Sjogren's syndrome disease activity(ESSDAI) score compared to the baseline at week 24 - 240 mg) , has been not met , according to Results published in the Rheumatology
  • 03 Jul 2023 Primary endpoint (The amount of change of European League Against Rheumatism Sjgrens syndrome disease activity(ESSDAI) score compared to the baseline at week 24 - 160mg) has been met as per results presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top